Please see the full-text version of this guideline https://www.cns.org/guidelines/guidelinestreatment-adults-metastatic-brain-tumors/chapter_2) for the target population of each recommendation listed below.
SURGERY FOR METASTATIC BRAIN TUMORS AT NEW DIAGNOSIS QUESTION:
Should patients with newly diagnosed metastatic brain tumors undergo surgery, stereotactic radiosurgery (SRS), or whole brain radiotherapy (WBRT)? RECOMMENDATIONS: Level 1: Surgery + WBRT is recommended as first-line treatment in patients with single brain metastases with favorable performance status and limited extracranial disease to extend overall survival, median survival, and local control. Level 3: Surgery plus SRS is recommended to provide survival benefit in patients with metastatic brain tumors Level 3: Multimodal treatments including either surgery + WBRT + SRS boost or surgery + WBRT are recommended as alternatives to WBRT + SRS in terms of providing overall survival and local control benefits.
SURGERY AND RADIATION FOR METASTATIC BRAIN TUMORS QUESTION:
Should patients with newly diagnosed metastatic brain tumors undergo surgical resection followed by WBRT, SRS, or another combination of these modalities? RECOMMENDATIONS: Level 1: Surgery + WBRT is recommended as superior treatment to WBRT alone in patients with single brain metastases. Level 3: Surgery + SRS is recommended as an alternative to treatment with SRS alone to benefit overall survival. www.neurosurgery-online.com S urgery is recommended for brain metastases that are large, have significant perilesional edema, result in neurological deficits, and present with uncertain pathology. In addition, surgery provides tissue diagnosis, when needed. Given the limitations of radiation therapy and other targeted therapies, surgery plays a critical role for patients.
METHODS
Details of the systematic literature review are provided in the full text of this guideline (https://www.cns.org/guidelines/guidelinestreatment-adults-metastatic-brain-tumors/chapter_2) and in the introduction and methods article (https://www.cns.org/guidelines/guidelinestreatment-adults-metastatic-brain-tumors/chapter_1) of this guideline series. The authors searched articles published from January 1, 2008 to December 31, 2015. Two electronic databases, PubMed and Ovid Medline, were searched ( Figure) . The selected articles were classified according to criteria for evidence on therapeutic efficacy and prognosis as detailed in the Joint Guidelines Committee Guideline Developmental Methodology (https://www.cns.org/guidelines/guideline-procedurespolicies/guideline-development-methodology).
RESULTS
A total of 1060 studies were evaluated for eligibility, and 121 publications met the eligibility criteria and were screened for inclusion. Of these, 32 studies met all the criteria and specifically focused on surgery for metastatic brain tumors either at initial diagnosis or at recurrence.
Should Patients With Newly Diagnosed Metastatic Brain Tumors Undergo Surgery, Stereotactic Radiosurgery, or Whole Brain Radiotherapy?
Consistent with previously published guidelines by Kalkanis et al, 1 class I evidence supports surgery plus whole-brain radiotherapy (WBRT) as a superior treatment modality to WBRT alone for patients with newly diagnosed metastatic brain tumors.
2-4 Class 3 evidence supports surgery plus stereotactic radiosurgery (SRS) as superior to SRS alone. 5, 6 Additionally, class ABBREVIATIONS: GTR, gross total resection; KPS, Karnofsky performance status; LMD, leptomeningeal disease; RPA, recursive partitioning analysis; SRS, stereotactic radiosurgery; WBRT, whole-brain radiotherapy III evidence supports the use of surgery as part of a multimodal treatment. Surgery plus WBRT plus radiation boost was found to be noninferior to WBRT plus SRS in terms of 1-yr local control, 1-yr intracerebral control, and 1-yr survival. 7 Similarly, surgery plus WBRT compared to WBRT plus SRS yielded similar rates of local control and overall survival at 1 or 5 yr. 
Should Patients With Newly Diagnosed Metastatic Brain Tumors Undergo Surgical Resection Followed by WBRT, SRS, or Other Combination of These Modalities?
Consistent with the previously published guidelines, 1 class I evidence supports surgery plus WBRT as a superior treatment modality to WBRT alone for single brain metastases. [2] [3] [4] Class III evidence supports surgery plus SRS as superior to SRS alone. 5, 6, 9 Class III evidence supports an equivalence in terms of overall survival between SRS alone and surgery + WBRT.
10,11

Should Patients With Recurrent Metastatic Brain Tumors Undergo Surgical Resection?
Class III evidence supports an association with improved survival and craniotomy for recurrence after initial surgery or stereotactic radiosurgery. 12, 13 However, attention should be given to preoperative functional status, age, extracranial disease, and the interval between SRS and resection prior to proceeding with craniotomy for recurrence.
Does Surgical Technique (En Bloc Resection or Piecemeal Resection) Affect Recurrence? Does the Extent of Surgical Resection (Gross Total Resection or Subtotal Resection) Affect Recurrence?
Class III evidence supports en bloc tumor resection to decrease the risk of postoperative leptomeningeal disease when resecting single brain metastases. [14] [15] [16] [17] Class III evidence supports gross total resection over subtotal resection in RPA class I patients to improve overall survival and prolong time to recurrence. 5, [18] [19] [20] 
SUMMARY AND DISCUSSION
In summary, these data demonstrate the benefit of initial surgery compared to radiation therapy alone. These results appear to be most relevant in patients with KPS > 70, 2 younger age, 5 favorable RPA class, 21 and lower Eastern Cooperative Oncology Group score, 5 control of primary tumor, 22 brain metastases diameter <4 cm, 23 and complete surgical resection. SRS, 7, 8 further studies are warranted to understand the appropriate use of surgery in terms of the number of brain metastases, tumor location, and optimal timing between surgery and adjuvant radiotherapies. The role of surgery for recurrence warrants further investigation with delineation between surgery and SRS as the initial treatment modality. Particularly attention should be directed at controlling for tumor location, size, and number of brain metastases. Analyses of surgical technique suggested that en bloc resection and GTR were superior surgical approaches and that piecemeal resection was associated with an increased risk of LMD. However, future studies will need to control for tumor size and location in addition to investigating the role of adjuvant radiation therapy in the setting of en bloc and piecemeal resection.
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